Microbial Colonization Clinical Trial
Official title:
Fecal Microbiota Transplantation for Eradication of Carbapenem-resistant Enterobacteriaceae Colonization: A Randomized Control Trial
Verified date | January 2020 |
Source | Rambam Health Care Campus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Antibiotic resistance has emerged world wide and is of major concern. Multidrug resistant (MDR) bacteria is widely spread and is now a major factor in morbidity and mortality in health-care settings. Among MDRs, carbapenem resistant Enterobacteriaceae (CRE) are of special concern, receiving the highest classification of "urgent threat level" in the US President Report. Consistent mortality rates of 40-50% are observed among inpatients with infections caused by CRE in hospitals worldwide, related mainly to unavailable, delayed or ineffective antibiotic treatment options. The extremely high mortality rates of patients with CRE infections have driven efforts to prevent the acquisition and spread of these bacteria in hospitals. These include screening for carriage, contact isolation of carriers, cohorting, dedicated healthcare staff and other infection control measures. These strategies have been proven as effective but are cumbersome and expensive. In most locations these strategies failed to completely eradicate CRE endemicity. CRE decolonization (eradication of colonization) might offer a double benefit - reducing the risk for the individual carrier to develop an infection due to the resistant strain (by that, potentially lowering the mortality risk) and preventing the bacteria from spreading to other patients, exposing them to the same hazard. Fecal microbiota transplantation (FMT), in which fecal material enriched with commensal microorganisms is transferred from a healthy donor, have proven efficacy in the treatment of recurrent Clostridium difficile infection (CDI) in multiple trails. Major adverse events that has been reported so far are mostly related to the route of administration (aspiration during nasogastric tube administration/colonoscopy). Other adverse events include mostly GI related symptoms (diarrhea, nausea, belching) and are self limited and resolve in few hours. FMT seems to be safe and effective both in immunocompetent and immunocompromised patients. The high efficacy of FMT in the treatment of a multi-drug resistant pathogen such as Clostridium difficile, suggest that it might be an efficient tool for other MDR pathogens (e.g. CRE). This study aim to assess the effects of FMT on colonization and clinical infections with CRE. The potential of FMT to restore the gut microbiome and compete with residual resistant strains offer a novel way to fight the current MDR epidemic. FMT will be applied in a randomized open label fashion to CRE carriers in a single center in Israel and will be given by capsules for 2 consecutive days followed by rectal sampling at predefined timepoint in the following 6 months.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 1, 2020 |
Est. primary completion date | January 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult inpatients =18 years positive for CRE of any strain and resistance mechanism in rectal surveillance stool samples, with or without CRE clinical samples. Positive rectal swab within one week before randomization will be mandatory. Exclusion Criteria: - Pregnant women - Patients with severe neutropenia (<100/µl) - Major abdominal surgery |
Country | Name | City | State |
---|---|---|---|
Israel | Rambam Health Care Campus | Haifa |
Lead Sponsor | Collaborator |
---|---|
Rambam Health Care Campus |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CRE Decolonization defined as 3 consecutive negative rectal samples for CRE | 3 consecutive negative rectal samples for CRE, last of which include a negative Polymerase chain reaction (PCR) test | 3 months after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05414994 -
Assessment of the Ocular Microbiome in Health and Disease
|
||
Completed |
NCT04769882 -
Er:YAG Laser Effects on Microbial Population in Conservative Dentistry
|
N/A | |
Completed |
NCT04766528 -
Effect of Diet on the Microbiota / Endoccanabinoidome Axis in Response to Physical Activity
|
N/A | |
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Completed |
NCT04122612 -
Shaping Microbiome in the First 1,000 Days of Life
|
||
Not yet recruiting |
NCT05405634 -
Microbiota in Chronic Anal Fissure and Its Association With Prognosis
|
||
Not yet recruiting |
NCT04895774 -
Ex Vivo Study of the Mechanism of Action of Active Ingredients on the Intestinal Microbiota
|
||
Recruiting |
NCT05992688 -
The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)
|
N/A | |
Recruiting |
NCT05502380 -
Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery
|
Phase 3 | |
Completed |
NCT05175833 -
Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19
|
Phase 2 | |
Recruiting |
NCT04836910 -
Microbiome and Polycystic Ovaries
|
||
Recruiting |
NCT05603650 -
Effects of Mouthrinses on the Microbiome of the Oral Cavity and GI Tract
|
N/A | |
Completed |
NCT05575050 -
Impact of Teeth Brushing in Ventilated COVID-19 Patients.
|
N/A | |
Completed |
NCT04991818 -
MSC - OneBiome UX Pilot Study
|
N/A | |
Completed |
NCT04374955 -
The Effect of Probiotic Added to Maternal Diet on Infantile Colic and Intestinal Microbiota Content
|
N/A | |
Recruiting |
NCT04140747 -
Transfer of Strictly Anaerobe Microbes From Mother to Child
|
||
Recruiting |
NCT04111471 -
The Use of A Prebiotic to Promote a Healthy Gut Microbiome in Pediatric Stem Cell Transplant Recipients
|
N/A | |
Suspended |
NCT03220282 -
The Milk, Growth and Microbiota Study
|
N/A | |
Completed |
NCT03422562 -
Probiotics and Intestinal Microbiome in Preterm Infants
|
Phase 3 | |
Recruiting |
NCT05695196 -
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant
|
Phase 1 |